Related references
Note: Only part of the references are listed.
Article
Oncology
Ishani Banik et al.
Summary: NRAS mutations are common in melanoma but lack targeted therapies. This study demonstrates that p38 acts as a tumor suppressor in NRAS mutant melanoma by regulating mTOR phosphorylation, autophagy, and actin remodeling. Pharmacologically available small molecules can modulate p38 and its downstream targets, providing a potential strategy for treating NRAS mutant melanoma. Combining these compounds with FDA-approved drugs like MEK inhibitors may offer a novel approach for targeting NRAS-mutant melanoma.
Review
Oncology
Qiang Ye et al.
Summary: Melanoma is a malignant and invasive cancer with increasing incidence. Current therapy options for melanoma are insufficient and challenging. Exosomes, particularly the miRNAs derived from them, have important roles in melanoma progression, diagnosis, and treatment. This review summarizes the functions of exosomal miRNAs in melanoma and their potential as diagnostic markers and therapeutic targets.
Article
Oncology
Rebecca L. Siegel et al.
Summary: The American Cancer Society predicts that there will be 1,958,310 new cancer cases and 609,820 cancer deaths in the United States in 2023. While incidence trends for most cancers are favorable, prostate cancer saw a significant increase of 3% annually from 2014 to 2019. However, the overall cancer death rate continues to decline due to advances in treatment, with a 33% reduction since 1991.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Article
Oncology
Kyu Young Song et al.
Review
Oncology
Chiara Pagliuca et al.
Summary: Late-stage melanoma frequently acquires resistance to standard therapies due to its plasticity in switching among different differentiation phenotypes. Understanding the origin and markers of this plasticity in melanoma can provide insights into developing new strategies to overcome treatment resistance.
Article
Oncology
Matea Kurtovic et al.
Summary: Researchers have found that the Hedgehog-GLI (HH-GLI) signaling pathway is involved in the development of melanoma and its interaction with the MAPK pathway. By using RNA sequencing and ChIP sequencing, they have identified new targets regulated by GLI proteins in melanoma cell lines and validated them through experiments. These findings contribute to a better understanding of the role of the GLI code in melanoma.
Review
Dermatology
Russell W. Jenkins et al.
Summary: The melanoma field has made significant clinical advances in the past decade, with improved therapeutic efficacy for advanced or metastatic melanoma. Targeted approaches and immunotherapy have become the primary treatment strategies, with targeted approaches showing high predictability of efficacy and immunotherapy leading to higher rates of durable remissions. These advancements have not only transformed the standard of care for patients but also suggested novel strategies to further enhance effectiveness for more patients.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2021)
Review
Pathology
Yan Zhou et al.
AMERICAN JOURNAL OF PATHOLOGY
(2019)
Article
Medicine, General & Internal
Dirk Schadendorf et al.
NATURE REVIEWS DISEASE PRIMERS
(2015)
